Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2011-02-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and
biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in
patients with epithelial ovarian cancer. This study will use a standard treatment regimen of
pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The
dose selected from this study will be used in a future studies to evaluate the efficacy of
this combination.